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Idelalisib impairs T-cell-mediated immunity in chronic
lymphocytic leukemia
In the last few years, new drugs able to inhibit the B-
cell receptor (BCR) pathway have been approved by the
US and European drug control agencies for the treatment
of chronic lymphocytic leukemia (CLL) and some indo-
lent B lymphomas. Among them, ibrutinib and idelalisib,
respectively, target the Bruton tyrosine kinase (BTK) and
the phosphatidylinositol 3-kinase δ (PI3Kδ), essential
molecules for transmitting the activation signals from
BCR that sustain malignant B cells.1 These inhibitors
were found to be particularly effective in CLL cases with
relapsed/refractory disease or presenting poor prognostic
factors and/or unfit for the best existing immunothera-
pies.2 After the initial excitement, the progressive occur-
rence of unwanted toxicities within the trials using ibru-
tinib or idelalisib has led to a more cautious use of these
drugs. The case of idelalisib is the most striking. In fact, a
high rate of serious adverse events, including deaths
related to infections including cytomegalovirus (CMV)
and pneumocystis jirovecii pneumonias (PJP), has caused
some clinical trials to be stopped.3 Now, after a careful
review by the drug agencies, a good risk-benefit balance
has been confirmed for this inhibitor, and strong recom-
mendations have been introduced to monitor treated
patients for the appearance of infection symptoms, and
to manage administration of  PJP prophylaxis and regular
CMV monitoring.4
Why idelalisib gives rise to these infections is still
unknown. We therefore decided to study how the drug
acts on the non-malignant counterpart of the immune
system in CLL patients, focusing on the T compartment.
PI3Kδ is known to be an intracellular transducer of T-cell
receptor (TCR) signaling and there is much evidence to
suggest it has an important role in the correct functioning
of T cells.5 Indeed, research studies conducted on mice
with p110δ deficiency found an impairment of T-cell pro-
liferation, differentiation, and cytokine production.6,7 In
accordance with this, experiments blocking PI3Kδ in
healthy human T cells showed an impaired production of
T-helper and inflammatory cytokines even if  no changes
in survival were seen.7,8
By hybridization on 4X44K whole human genome
microarray, we performed a gene expression profile
(GEP) analysis on total RNA of T cells purified from
peripheral blood mononuclear cells (PBMCs) of untreated
CLL patients. T cells were incubated in the presence or
absence of 5 mM idelalisib for 1 hour (h) and stimulated
with antiCD3 antibody for 4 h. Experiments are
described in the Online Supplementary Methods and in
Online Supplementary Figure S1. Comparing the GEP
between control (no treatment/no stimulation), antiCD3
(antiCD3 stimulation alone) and antiCD3+ide (antiCD3
stimulation with drug pre-treatment), we first identified
haematologica 2018; 103:e598
LETTERS TO THE EDITOR
Figure 1. Idelalisib reduces the cytokine expression in activated T cells of chronic lymphocytic leukemia (CLL) patients. (A) Supervised hierarchical clustering
of gene expression profiles in RNA samples of T cells purified from 4 CLL patients, each cultured with the three following conditions: i) control (CTRL, no treat-
ment/no stimulation); ii) antiCD3 (stimulation with antiCD3 antibody); iii) antiCD3+ide (5 mM idelalisib pre-treatment followed by antiCD3 stimulation). Shown
are genes differentially expressed between the described conditions, compared by Anova test; P≤0.01. Green squares: low levels of transcript; red squares: high
levels of transcript; black squares: equal level of transcript. Complete microarray data are deposited in the NCBI Gene Expression Omnibus (GEO,
http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO accession number GSE108224. (B) Expression levels of IL-2, TNFα and IFNg were mea-
sured by real-time PCR in RNA samples of T cells purified from 5 CLL patients and cultured with the same three conditions described in (A). Values are repre-
sented by the histograms as mean±Standard Error and normalized to CTRL values, defined as 1. IL-2, TNFα and IFNg are significantly up-regulated by antiCD3
stimulation but idelalisib strongly abrogates these inductions (*P<0.05, Student t-test). 
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the differentially expressed genes with Anova (P≤0.01
was considered significant). Among these, we focused on
the 65 genes with fold-change [FC]≥2 between the
“antiCD3” and “antiCD3+ide” conditions (Figure 1A). Of
the 61 genes down-regulated by idelalisib, the most re-
presented categories were chemokines involved in T-cell
migration (such as CXCL9-10-11), inflammatory and T-
helper cytokines (such as IL-2, TNFα, IFNg, IL-13, IL-21),
mitogenic signal transducers (such as IRF4, STAT1,
EGR1-2-3-4) and receptors (such as CD69, CD25) com-
monly induced during activation of T cells (Online
Supplementary Table S1). These data indicate that 
idelalisib reduces the expression of important genes for 
T-cell-mediated immunity in CLL, so we searched for
possible drug interferences with cytokine production,
migration and proliferation of T cells.
We used real-time PCR to evaluate the mRNA expres-
sion of some inflammatory cytokines in T cells purified
from CLL patients, pre-blocked or not with idelalisib, and
stimulated with antiCD3 antibody, as previously
described for GEP experiments. We observed that
amounts of IL-2, TNFα and IFNg increased 6.9, 7.9 and
13.3-fold in T cells stimulated by antiCD3 (P=0.009,
P=0.008 and P=0.026, respectively) in comparison to
non-stimulated controls (Figure 1B). In the presence of
idelalisib, we found that IL-2, TNFα and IFNg expressions
decreased 4.0, 5.2 and 6.3 times if compared to antiCD3
stimulation alone (P=0.008, P=0.007 and P=0.033,
respectively) (Figure 1B). Moreover, we performed
ELISpot analyses using Human IFN-g ELISpotPRO (ALP)
to verify the effect of idelalisib on IFNg protein release by
T cells of CLL patients, stimulated or not with antiCD3
antibody for 18 h. In parallel, we cultured T samples with
100 ng/mL PepMIX HCMVA (pp65) (peptide mix of
CMV phosphoprotein 65) or 100 ng/mL CEF [peptide
mix of CMV, Epstein Barr virus (EBV) and influenza virus]
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Figure 2. IFNg release from stimulated T cells is
impaired by idelalisib in chronic lymphocytic
leukemia (CLL). (A) ELISpots for IFNg release were
performed on T samples obtained from 5 CLL
patients and 4 healthy donors (HD), stimulated or
not with antiCD3 antibody, cytomegalovirus (CMV)
or CEF peptides, in the presence or absence of 5 µM
idelalisib. In the graph, the spot number obtained
with the drug is indicated as mean
percentage±Standard Error (SE)  of the spot number
observed with the correspondent stimulation,
defined as 100%. Black squares: HD; white squares:
CLL. Since control (CTRL, no treatment/no stimula-
tion) and CTRL+ide (idelalisib treatment/no stimula-
tion) conditions showed the same IFNγ spot number
(usually zero) for all CLL and HD T samples, they
have not been included in the graph. The increased
production of IFNg induced in T cells by each stimu-
lation is significantly decreased by idelalisib, both
for CLL and HD (*P<0.05, Student t-test). (B) IFNγ
cytokine secretion assays (CSA) were performed on
T samples collected from 5 CLL patients, pre-treated
or not with 5 mM idelalisib and stimulated or not
with antiCD3 antibody. We acquired approximately
100,000 events inside the “lymphocytes” gate and
the analysis identified the IFNg+ lymphocytes inside
the CD3+CD8+ or CD3+CD4+ gates. In the graph, the
mean percentages±SE of CD3+CD8+IFNg+ and
CD3+CD4+IFNg+ lymphocytes are represented with
black squares and with gray squares, respectively.
Control (CTRL, no treatment/no stimulation) and
CTRL+ide (idelalisib treatment/no stimulation)
show substantially the same percentages of
CD3+CD8+IFNg+ and CD3+CD4+IFNg+ lymphocytes
(P=n.s., Student t-test). With antiCD3 stimulation,
these percentages become respectively 2.3 and
3.1-fold higher in comparison to CTRL (*P<0.05,
Student t-test). The presence of idelalisib under
stimulation reduces the percentages of
CD3+CD8+IFNg+ and CD3+CD4+IFNg+ lymphocytes by
1.7 and 2.4 times, respectively, if compared to
antiCD3 stimulation alone (*P<0.05, Student 
t-test). n.s.: not significant.
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for 18 h, in the presence or absence of 5 mM idelalisib,
looking for any modulation in T-cell responses to these
viruses. We confirmed that the IFNg release by T samples
promoted by antiCD3 stimulation is reduced by 53.2% in
the presence of idelalisib (P<0.001) (Figure 2A).
Interestingly, the drug decreased cytokine production
also in T cells stimulated by CMV (reduced by 58.4%,
P=0.009) or CEF peptides (reduced by 64.4%, P=0.003)
(Figure 2A). Performing similar ELISpot tests on T sam-
ples collected from healthy donors (HD), we found that
idelalisib diminishes the IFNg release induced by each
stimulation (reduced by 27.7% for antiCD3 antibody, by
29.4% for CMV peptides, and by 43.7% for CEF pep-
tides, respectively; all P<0.05) (Figure 2A). In the absence
of stimulation, the drug did not modify the number of
IFNγ spots for either CLL or HD T-cell samples. Together
these show that idelalisib impairs IFNg production by
activated T cells, supporting the crucial role of PI3Kδ in
this process, both in CLL and in healthy donors. Since the
drug inhibits T cells not only in the case of generic TCR
stimulation, but also in response to virus-specific stimu-
lation, it could favor a higher rate of CMV reactivations
in those CLL patients who are treated with it.
We also studied the possible different action of idelali-
sib towards the CD4 or  the CD8 T-cell subset, by per-
forming IFNg cytokine secretion assays (CSA) on T sam-
ples collected from CLL patients, pre-treated or not with
5 mM idelalisib and stimulated or not with antiCD3 anti-
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Figure 3. Idelalisib inhibits T-cell migration and proliferation in chronic lymphocytic leukemia (CLL). (A) Migration experiments were performed on T cells puri-
fied from 5 CLL patients, in presence or in absence of 5 mM idelalisib [Control (CTRL)+ide and CTRL, respectively]. The histograms represent the mean 
percentages±Standard Error (SE) of migrated cells normalized to CTRL, defined as 100%. The drug strongly reduced the number of T cells that spontaneously
migrated (*P<0.05, Student t-test). (B) T cells purified from 6 CLL patients were stimulated with CXCL10 in the presence or absence of 5 mM idelalisib and tested
for their migration. The mean percentage±SE of migrated T cells was normalized to CTRL (no treatment/no stimulation), defined as 100%. The number of 
migrated cells is increased by CXCL10 stimulation but is significantly decreased by idelalisib (*P<0.05, Student t-test). (C) Proliferation ability was evaluated by
flow cytometry by analyzing the CFSE dilution peaks in T cells purified from 3 CLL patients, pre-treated or not with 5 mM idelalisib and stimulated with a mix of
antiCD3+antiCD28+antiCD2 antibodies and IL-2. Not treated/non-stimulated cells were used as controls (CTRL). The mean percentages±SE of proliferating 
T cells are represented by the histograms. The increased T-cell proliferation obtained with stimulation is significantly reduced by the drug (*P<0.05, Student 
t-test). (D) Strategy example for the flow-cytometry analysis of T-cell proliferation in the three tested conditions: i) CTRL (not treated/non-stimulated cells), 
ii) stimulation (stimulation with a mix of antiCD3+antiCD28+antiCD2 and IL-2), iii) stimulation+ide (pre-treatment with 5 µM idelalisib followed by stimulation
with a mix of antiCD3+antiCD28+antiCD2 and IL-2). We acquired approximately 10,000 events inside the “lymphocytes” gate based on FSC-H and SSC-H 
features. For the analysis, inside this first gate we drew a “CD3, SSC-H subset” gate, including only CD3+ cells. Inside this last gate, we evaluated the CFSE 
dilution peaks of proliferating cells, located to the left of the baseline CFSE peak identified based on the CTRL. For each studied case, we drew the same gates
for all three conditions. In the single box on the bottom right, the CSFE dilution peaks of T cells are overlapped and compared between the described conditions.
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body for 1 h. CD3+CD8+IFNg+ and CD3+CD4+IFNg+ popu-
lations were significantly increased by antiCD3 stimula-
tion but were significantly reduced by idelalisib (both
P<0.05) (Figure 2B). Therefore, the drug seems to affect
IFNg production in both CD4 and CD8 T-cell subsets.
We then investigated the effect of idelalisib on the
migration ability of T cells of CLL patients in vitro. T cells
purified from CLL cases were pre-treated or not with 5
mM idelalisib and were left to migrate for 2 h in the pre-
sence or absence of 100 ng/mL CXCL10. We found that
the PI3Kδ inhibitor reduced the percentage of T cells that
spontaneously migrated from 100% to 66.7±9.0%
(P=0.022) (Figure 3A). When we added CXCL10 as
chemoattractant, T-cell migration increased from 100%
to 206.9%±40.5% but it was reduced to 136.7%±44.8%
in the presence of the drug (both P<0.05) (Figure 3B).
These data suggest that idelalisib is able to hamper the
migration of T cells of CLL patients, even when they are
attracted by proper chemokines. 
Finally, we evaluated the action of idelalisib on T-cell
proliferation in CLL. T cells purified from CLL cases were
stained with CFSE, pre-treated or not with 5 mM 
idelalisib and then stimulated with a mix of
antiCD3+antiCD28+antiCD2 antibodies and 300 U/mL
IL-2 for 72 h. The percentage of proliferating T cells
increased 6.15-fold after stimulation (P<0.001) but
decreased 1.27 times in the presence of the drug (P<0.05)
(Figure 3C and D). We also measured T-cell vitality in
PBMCs of CLL patients treated or not with 1 mM or 5 mM
idelalisib in vitro for 24 and 48 h and found no significant
changes when compared to controls (data not shown), in
accordance with existing literature.6 The PI3Kδ inhibitor
can, therefore, reduce the proliferative capacity of T cells
of CLL patients in response to strong stimulations, with-
out affecting their survival.
In conclusion, our study has demonstrated the
inhibitory effect of idelalisib towards several important
functions of T cells of CLL patients, in particular cytokine
production, migration and proliferation, in response to
stimulation. Interestingly, the drug-blocking action was
observed also in T cells stimulated with CMV, EBV or
influenza antigens. CMV-specific immunity has previous-
ly been demonstrated to play a crucial role in controlling
infection by this virus.9 In immunocompromised hosts,
CMV infections are often found to accompany PJP, possi-
bly sharing some immunogenic mechanism, although the
precise biological reasons are unknown.10 Our in vitro data
suggest that idelalisib can impair T-cell-mediated
responses to CMV, giving one possible explanation for
the high frequency of CMV-reactivations and PJP
observed in CLL cases treated with this drug. A very
recent paper has observed an increased percentage of
Tregs by immunohistochemistry in biopsies of patients
who received idelalisib and experienced gastrointestinal
symptoms, sometimes in association with PCR positivity
for infectious pathogens.11 These findings, together with
our results, support the hypothesis that a T-cell impair-
ment induced by idelalisib, able to favor infections and/or
viral reactivations, can be responsible for some important
side-effects of the drug. Certainly, the role of Tregs in this
context remains to be elucidated. Future functional
experiments conducted on T samples collected from CLL
patients in the course of treatment with idelalisib will be
helpful to better clarify the drug effect on the different T-
cell subsets in vivo. Similarly, the impact of ibrutinib on
either innate or adaptive immunity warrants further
investigation, given the recent reports of invasive fungal
infections in treated patients.12,13 Increasing the 
knowledge of biological effects of such TK inhibitors on
non-malignant cells may promote their proper and
appropriate use, through the early recognition, 
monitoring and prevention of those infectious 
complications that could possibly be drug-related.    
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